Top

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET inhibitors for treating a difficult-to-treat form of lymphoma.

Research findings were published online in Science Translational Medicine.

The study, led by Michael Green, Ph.D., assistant professor of Lymphoma & Myeloma, showed that transcription factor 4 (TCF4) is the most frequent...

Michael Green, Ph.D.

BY Scott Merville

MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...

BY Ron Gilmore

Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous ribonucleoprotein K (hnRNPK), appears to lead to cancer development when overexpressed and may lead to new methods for assessing patients and to the development of new lymphoma treatment approaches.

Findings from the study, led by Sean Post, Ph.D., associate professor of Leukemia at MD Anderson...

Sean Post, Ph.D.

BY Bryan Tutt

Recently approved targeted and immunotherapy drugs are helping patients diagnosed with follicular lymphoma live longer. Knowing the available...

BY Ron Gilmore

Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma...

BY Scott Merville

Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...

BY Sarah Bronson

Two new clinical trials at MD Anderson are taking aim at mantle cell lymphoma – a rare form of non-Hodgkin’s lymphoma.

Most mantle...

BY Ron Gilmore

ONC201, an anti-cancer drug that triggers cell death in various tumor types, may be effective in treating some blood cancers, including mantle...

BY Scott Merville

MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...